» Articles » PMID: 25799237

Codon Optimization of the Human Papillomavirus E7 Oncogene Induces a CD8+ T Cell Response to a Cryptic Epitope Not Harbored by Wild-type E7

Overview
Journal PLoS One
Date 2015 Mar 24
PMID 25799237
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Codon optimization of nucleotide sequences is a widely used method to achieve high levels of transgene expression for basic and clinical research. Until now, immunological side effects have not been described. To trigger T cell responses against human papillomavirus, we incubated T cells with dendritic cells that were pulsed with RNA encoding the codon-optimized E7 oncogene. All T cell receptors isolated from responding T cell clones recognized target cells expressing the codon-optimized E7 gene but not the wild type E7 sequence. Epitope mapping revealed recognition of a cryptic epitope from the +3 alternative reading frame of codon-optimized E7, which is not encoded by the wild type E7 sequence. The introduction of a stop codon into the +3 alternative reading frame protected the transgene product from recognition by T cell receptor gene-modified T cells. This is the first experimental study demonstrating that codon optimization can render a transgene artificially immunogenic through generation of a dominant cryptic epitope. This finding may be of great importance for the clinical field of gene therapy to avoid rejection of gene-corrected cells and for the design of DNA- and RNA-based vaccines, where codon optimization may artificially add a strong immunogenic component to the vaccine.

Citing Articles

Identification of novel HLA-A*11:01-restricted HPV16 E6/E7 epitopes and T-cell receptors for HPV-related cancer immunotherapy.

Xiong C, Huang L, Kou H, Wang C, Zeng X, Sun H J Immunother Cancer. 2022; 10(9).

PMID: 36180070 PMC: 9528665. DOI: 10.1136/jitc-2022-004790.


Therapeutic DNA Vaccines against HPV-Related Malignancies: Promising Leads from Clinical Trials.

Tang J, Li M, Zhao C, Shen D, Liu L, Zhang X Viruses. 2022; 14(2).

PMID: 35215833 PMC: 8874761. DOI: 10.3390/v14020239.


Strategies to Genetically Modulate Dendritic Cells to Potentiate Anti-Tumor Responses in Hematologic Malignancies.

Cornel A, van Til N, Boelens J, Nierkens S Front Immunol. 2018; 9:982.

PMID: 29867960 PMC: 5968097. DOI: 10.3389/fimmu.2018.00982.


Unbiased Identification of T-Cell Receptors Targeting Immunodominant Peptide-MHC Complexes for T-Cell Receptor Immunotherapy.

Lorenz F, Ellinger C, Kieback E, Wilde S, Lietz M, Schendel D Hum Gene Ther. 2017; 28(12):1158-1168.

PMID: 28950731 PMC: 5737719. DOI: 10.1089/hum.2017.122.


HPV disease transmission protection and control.

Christensen N Microb Cell. 2017; 3(9):476-490.

PMID: 28357382 PMC: 5354572. DOI: 10.15698/mic2016.09.530.


References
1.
Shiver J, Fu T, Chen L, Casimiro D, Davies M, Evans R . Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature. 2002; 415(6869):331-5. DOI: 10.1038/415331a. View

2.
Tindle R . Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002; 2(1):59-65. DOI: 10.1038/nrc700. View

3.
Ho O, Green W . Alternative translational products and cryptic T cell epitopes: expecting the unexpected. J Immunol. 2006; 177(12):8283-9. DOI: 10.4049/jimmunol.177.12.8283. View

4.
Bodles-Brakhop A, Heller R, Draghia-Akli R . Electroporation for the delivery of DNA-based vaccines and immunotherapeutics: current clinical developments. Mol Ther. 2009; 17(4):585-92. PMC: 2835112. DOI: 10.1038/mt.2009.5. View

5.
Benteyn D, Anguille S, Van Lint S, Heirman C, Van Nuffel A, Corthals J . Design of an Optimized Wilms' Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo. Mol Ther Nucleic Acids. 2013; 2:e134. PMC: 3889186. DOI: 10.1038/mtna.2013.54. View